GLP-1 receptor agonist (acylated GLP-1 analogue)
Liraglutide
An approved acylated GLP-1 receptor agonist and an earlier Novo Nordisk analogue than semaglutide. Generic versions are listed in Drugs@FDA, and FDA named liraglutide with semaglutide and tirzepatide in its April 2026 proposal on the 503B bulks list.
Why people are interested in Liraglutide
An approved acylated GLP-1 receptor agonist and an earlier Novo Nordisk analogue than semaglutide. Generic versions are listed in Drugs@FDA, and FDA named liraglutide with semaglutide and tirzepatide in its April 2026 proposal on the 503B bulks list.
- Incretin analogues— a research-category classification, not a claimed use
- Approved drug substances— a research-category classification, not a claimed use
Where the interest comes from differs by compound: published research, an approved use, clinical discussion, community discussion and vendor claims are different things. This page keeps them apart — the sections below say which kind of source supports each statement.
Quick facts
- Molecular weight
- 3751.2 Da (FDA label); 3751 g/mol (PubChem)
- Sequence length
- 181 chars
- CAS number
- 204656-20-2
- PubChem CID
- 16134956
0 evidence records indexed · 0 clinical trials · last reviewed 15 September 2026
Research at a glance
No evidence records in this file yet.
What has actually been studied
What is still unknown
What we know
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
Dosing reference
An approved drug with a labelled dose schedule. The label is the authoritative source; research-chemical copies of liraglutide are not the labelled product.
The dosing reference presents official label doses, published human study parameters, animal-study data, clinical references and community-reported ranges — each in its own section, never blended into one number.
Open the Liraglutide dosing referencePreparation and handling
Lyophilized peptides ship as powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific. Therapept’s preparation guides explain the vocabulary and the arithmetic; the product’s own documentation states its requirements.
United States regulatory status
FDA-approved drug substance
NDA 022341 (VICTOZA), NDA 206321 (SAXENDA); abbreviated applications for generic liraglutide
Marketed in the United States as VICTOZA (glycaemic control in type 2 diabetes mellitus, and reduction of major adverse cardiovascular event risk in adults with type 2 diabetes and established cardiovascular disease) and SAXENDA (weight reduction and long-term maintenance in specified adult and paediatric populations). Generic liraglutide products are also approved.
- VICTOZA, NDA 022341, approved 25 January 2010. SAXENDA, NDA 206321, approved 23 December 2014. Both are listed as prescription products in Drugs@FDA.
- Drugs@FDA lists abbreviated new drug applications for generic liraglutide, the earliest dated 23 December 2024.
- FDA proposed in April 2026 to exclude liraglutide, semaglutide and tirzepatide from the 503B bulks list.
- Not named on the WADA 2026 Prohibited List.
Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.
Technical identity
- Compound class
- GLP-1 receptor agonist (acylated GLP-1 analogue)
- Sequence
- GLP-1(7-37) analogue with arginine substituted for lysine at position 34 and a C-16 palmitic acid attached through a glutamic acid spacer to lysine 26, as described in the FDA label
- Molecular formula
- C172H265N43O51
- Molecular weight
- 3751.2 Da (FDA label); 3751 g/mol (PubChem)
- CAS number
- 204656-20-2
- PubChem CID
- 16134956
- Research categories
- Incretin analogues, Approved drug substances
Sources
Last reviewed 15 September 2026 · Compiled by Therapept Editorial · How these records are built